Marinus Pharmaceuticals
Commercial-stage pharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of seizure disorders and neuropsychiatric conditions.
Location
Radnor, Pennsylvania, USA
Founded
2003
Categories
pharma, neurology, rare-disease, epilepsy, therapeutics
Notes
Marinus Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing and commercializing therapeutics for patients with seizure disorders and neuropsychiatric conditions. The company's lead product, ZTALMY (ganaxolone), is FDA-approved for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare genetic epilepsy.
Listed on NASDAQ under the ticker MRNS, Marinus is also developing ganaxolone for other rare epilepsies and status epilepticus, leveraging its expertise in neuroactive steroids.
Team
- Scott Braunstein, M.D. - Chairman & Chief Executive Officer
- LinkedIn: linkedin.com/in/scottbraunstein
- Steve Pfanstiel - Chief Financial Officer
- Joseph Hulihan, M.D. - Chief Medical Officer
Additional Research Findings
- Founded in 2003
- Headquarters in Radnor, Pennsylvania
- Listed on NASDAQ (MRNS)
- Portfolio company of Bain Capital Life Sciences
- ZTALMY (ganaxolone) - first FDA-approved treatment for CDD
- Focus on GABAergic neuroactive steroids
- Pipeline includes programs in status epilepticus and tuberous sclerosis complex
- Orphan drug designations for multiple indications